Modified protamine with reduced immunogenicity
本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽,其中,所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对鱼精蛋白进行修饰以产生在体内使用时基本上无免疫原性,或比未经修饰的相应蛋白免疫原性低的鱼精蛋白。 The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides wh...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 本发明涉及尤其是用于对人施用的、特别是用于治疗的多肽。所述的多肽是经修饰的多肽,其中,所述的修饰使得上述多肽在施用于人体时引起免疫应答的倾向减弱。本发明特别涉及对鱼精蛋白进行修饰以产生在体内使用时基本上无免疫原性,或比未经修饰的相应蛋白免疫原性低的鱼精蛋白。
The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of protamine to result in protamine proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. |
---|